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ABSTRACT 
 
 Quiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme that catalyzes disulfide 
bond formation by oxidizing two free sulfhydryl groups. QSOX1 consists of a 
thioredoxin (Trx) and an ERV (essential for respiration and viability)/ALR (augmenter of 
liver regeneration) domain which each contain CxxC motifs that work to bind to 
substrates and shuttle electrons to a flavin adenine dinucleotide (FAD) cofactor that 
accepts the electrons and reduces molecular oxygen to hydrogen peroxide. Investigation 
of the role of QSOX1 in cancer progression started when it was found at higher 
abundance in pancreatic ductal adenocarcinoma (PDA) patient plasma compared to 
healthy normal donor plasma. Increased expression in QSOX1 has been further identified 
in breast, lung, kidney, prostate, and other cancers. QSOX1 expression is associated with 
cell proliferation and invasion in vitro and tumor growth in vivo. Additionally, the 
enzymatic activity of QSOX1 in the extracellular matrix (ECM) is important for cell 
invasion in vitro. Small molecule inhibitors of QSOX1 have been shown to have 
antitumorigenic properties in vitro and in vivo. It was hypothesized that monoclonal 
antibodies (mAbs) against QSOX1 would inhibit cell invasion in vitro. In this work, mice 
were immunized with eukaryotic-derived rQSOX1 for generation of hybridomas. 
Hundreds of hybridoma clones were screened by enzyme-linked immunosorbent assay 
(ELISA) and a fluorescent QSOX1 activity assay. Multiple rounds of subcloning and 
screening identified 2F1.14 and 3A10.6 as mAbs of interest. The genes for the variable 
regions of the antibodies were rescued and sequenced. The sequences were aligned with 
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the variable region sequences of another published αQSOX1 mAb scFv492.1. 2F1.14 
inhibits the enzymatic activity of QSOX1 by binding to the active site of QSOX1, which 
was determined by epitope mapping against mutants of QSOX1 that contained mutations 
in the active site. 3A10.6 did not appear to inhibit the function of QSOX1 in the activity 
assay; however, it, along with 2F1.14, suppressed tumor invasion in a 3D invasion model. 
These findings support the developing idea that QSOX1 is a viable target for cancer 
treatment because targeted inhibition of QSOX1 extracellularly reduced invasive activity. 
The mAbs and rQSOX1 variants produced here can serve as tools in furthering the 
characterization of QSOX1 and its role in cancer.  
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INTRODUCTION 
 
 Cancer is the second leading cause of death in the United States and is on the rise 
to become the leading cause overall (Centers for Disease Control and Prevention). Men 
and women are at a 38.4% risk of being diagnosed with cancer during their lifetime. 
49.4% of cancer deaths are caused by bladder, breast, renal, lung, pancreatic, and prostate 
cancers, with pancreatic cancer having an astonishingly low survival rate of 8.5% within 
five years of diagnosis (National Cancer Institute). Quiescin sulfhydryl oxidase 1 
(QSOX1) is associated with each of these tumor types, and the amount of evidence 
supporting the idea that QSOX1 has significant involvement in cancer progression has 
been growing over the past decade. 
 QSOX1 is an enzyme that catalyzes formation and shuffling of disulfide bonds of 
client proteins in the endoplasmic reticulum (ER), Golgi apparatus, and in the 
extracellular matrix (ECM) (Hoober et al. 1996; Mairet-Coello et al. 2004; Jaje et al. 
2007). It was initially discovered as being a part of a group of genes that are expressed in 
human lung fibroblasts that had reached quiescence, originally being named Q6 in a 
group called quiescins, which also includes ECM proteins decorin and collagen (Coppock 
et al. 1991). There are two forms of QSOX1, a short form (QSOX1-S) and a long form 
(QSOX1-L). The QSOX1-S is 604 amino acids long, while QSOX1-L is 747 amino acids 
long. The additional 143 amino acids contained in QSOX1-L is added C-terminal to 
QSOX1-S and contains a transmembrane domain (Radom et al. 2006). The short form of 
QSOX1 is dominantly excreted by cells (Stirling et al. 2007), and there is evidence that 
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shows that QSOX1-L is proteolytically cleaved into QSOX1-S, removing the 
transmembrane domain, allowing for the secretion of QSOX1-S into the ECM (Rudolf, 
Pringle, and Bulleid 2013). 
 In addition to the transmembrane domain, QSOX1 contains three major domains: 
two Trx-like (thioredoxin) domains (Trx1 and Trx2), an ERV (essential for respiration 
and viability)/ALR (augmenter of liver regeneration) domain, and a FAD (flavin adenine 
dinucleotide)-binding domain (Coppock, Cina-Poppe, and Gilleran 1998; Hoober et al. 
2002). There are also three CxxC motifs (two cysteines separated by any two amino 
acids); one located in the Trx1 domain (C70-C73), one in the ERV/ALR domain (C449-
452), and one a few amino acids downstream of the FAD-binding domain (C509-512) 
(Hoober et al. 2002). The mechanism of QSOX1 utilizes two of these CxxC motifs and a  
 
 
Figure 1: Schematic of the domains and motifs of QSOX1. Trx domains are in blue, 
pseudo ERV domain is denoted with ΨERV in yellow and ERV/ALR in green. CxxC 
motifs and FAD cofactor binding are labelled. 
 
FAD molecule to generate disulfide bonds from free sulfhydryl groups in substrates 
(Heckler et al. 2008). This mechanism was determined by mutating the cysteine residues 
in the motifs, which found that mutation of C70, C73, C449, and C452 caused almost 
complete loss of enzymatic function. The C509-C512 CxxC motif has been found to have 
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no contribution to the enzymatic activity of QSOX1 in a study in which the motif was 
mutated and enzymatic activity remained (Heckler et al. 2008) 
 The enzymatic activity of QSOX1 has been characterized utilizing a number of 
substrates including dithiothreitol (DTT) and reduced RNase A in fluorescence-based 
assays (Raje, Glynn, and Thorpe 2002), as well as a luciferase from copepod Gaussia 
princeps (GLuc) in a luminescence-based assay (Yu et al. 2018). The activity assays with 
DTT and reduced RNase A rely on the production of hydrogen peroxide (H2O2) as a 
byproduct of QSOX1 forming disulfide bonds from free sulfhydryl groups. H2O2 is 
consumed in a secondary reaction with horseradish peroxidase (HRP) and homovanillic 
acid (HVA) in which HRP creates a fluorescent dimer of HVA. The fluorescence of the 
HVA dimer is proportional to the amount H2O2 present in the assay, and thusly is 
proportional to the activity of QSOX1. The luminescence assay utilizes GLuc, which has 
the distinct characteristic of containing ten cysteines that are involved in disulfide 
bonding and has little to no luminescent activity when reduced. QSOX1 oxidizes and 
folds reduced GLuc, creating a functional luciferase. When GLuc substrate 
(coelenterazine) is added, a measurable luminescent signal is generated. This assay works 
independently of any H2O2 detection reaction, which is beneficial because interaction of 
substrates or potential inhibitors with HRP or HVA is no longer a concern. QSOX1 
activity can also be measured by Clark-type electrode, which measures the amount of 
molecular oxygen in a solution using a platinum surface that electrolytically reduces 
oxygen by donating electrons ran through the platinum electrode and a silver electrode 
(Clark et al. 1953). When QSOX1 is added, the amount of oxygen reacting with the 
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platinum electrode decreases as more substrate is consumed (Hoober et al. 1996; Raje 
and Thorpe 2003). This method provides another way of measuring the activity of 
QSOX1 independent of a secondary reaction; however, this method does not allow for 
high-throughput analysis of different conditions for QSOX1 activity. 
The current model of the mechanism of QSOX1 is that substrates initially interact 
with the C70-C73 motif in the Trx-like domain by creating a disulfide bond with C73, 
after which electrons are shuttled to the C449-C452 motif and are ultimately donated to 
FAD, where molecular oxygen is reduced to hydrogen peroxide as result of substrate 
oxidation (Heckler et al. 2008; Alon et al. 2012). The ability of the C70-C73 motif to 
shuttle electrons to the C449-C452 motif relies on a hinge-like action that brings the two 
motifs at opposite ends of the enzyme together after a substrate has interacted with the 
C70-C73 motif (Gat et al. 2014). This hinge-like action has been associated with a cis-
proline (P119) which has been shown to be crucial to both the enzymatic and biological 
activity of QSOX1. Mutation of this proline residue to a threonine resulted in loss of 
enzymatic function and exogenous addition of this P119T mutant to fibroblast cell culture 
causes disruption of fibronectin in the ECM (Javitt et al. 2018). QSOX1 has been shown 
to be involved with other ECM proteins as well, including laminin α4. WI-38 lung 
fibroblast QSOX1 knockdowns had significantly lesser amounts of laminin deposition 
into the ECM, which was later characterized to be laminin α4 specifically (Ilani et al. 
2013).  
 Investigation of the role of QSOX1 in cancer started in 2009 when a peptide 
(NEQEQPLGQWHLS) from the extra 143 amino acids contained in QSOX1-L was 
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found through mass spectrometry analysis of the plasma peptidome of patients with 
pancreatic ductal adenocarcinoma (PDA) (Antwi et al. 2009). This peptide was found in 
16 out of 23 patients with PDA and was absent from 42 healthy normal donors. This 
study marked QSOX1 as a potential marker of cancer, and the reason for its expression 
only in pancreatic cancer patients compared to normal healthy donors was investigated. 
QSOX1 expression was suppressed by stably transducing two pancreatic cancer cell lines 
(Panc-1 and BxPC3) with short-hairpin RNAs (shRNAs) targeting QSOX1 and looking 
at the effect on hallmark cancer characteristics (Katchman et al. 2011). QSOX1 
knockdown resulted in several interesting changes: cell proliferation and invasion both 
decreased in three different knockdown clones. The mechanism in which QSOX1 is 
involved in invasion was studied, and it was found that QSOX1 knockdowns caused a 
decrease in matrix metalloproteinase (MMP) activity, specifically MMP-2, by gelatin 
zymography compared to shScramble controls. Additionally, the transcription levels of 
MMPs were found to be unaffected by the knockdown of QSOX1, supporting the idea 
that QSOX1 posttranslationally activates MMPs. 
 The observations of QSOX1 and its role in pancreatic cancer were then looked at 
in breast cancer (Katchman et al. 2013). The same shRNA QSOX1 knockdowns were 
made in MCF7, BT549, and BT474 cell lines. Similar observations were made in these 
knockdown experiments: cell proliferation and cell invasion decreased compared to 
shRNA controls. Again, MMPs were investigated; however, in the breast cancer cell 
lines, it was MMP-9 that showed decreased activation in QSOX1 knockdown cells. This 
data supported the ongoing hypothesis that QSOX1 was a potential prognostic marker for 
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aggressive tumors. On the contrary, there was another group that previously published 
data suggesting that QSOX1is a marker of a good prognosis for patients (Pernodet et al. 
2012). The data showed that knockdown of QSOX1 expression caused a decrease in cell 
proliferation, and a decrease in cell invasion. A third group set out to look at expression 
of QSOX1 and its prognostic value by immunohistochemistry (IHC) on breast cancer 
patient tumors (Knutsvik et al. 2016). Tissue staining with αQSOX1 antibodies was given 
a score on a staining index, and those scores were matched with different 
histopathological variables. It was determined from this study that QSOX1 expression 
was associated with markers of poor prognoses, like high grade, hormone receptor 
negativity, human epidermal growth factor receptor 2 (HER2) positivity, and increased 
tumor cell proliferation, as well as lower survival rates. These findings support the 
hypothesis that QSOX1 is a biomarker for more invasive, aggressive tumors. This 
hypothesis is further supported by data from lung and prostate cancer investigations, in 
which QSOX1 was associated with high grade, aggressive tumors (Baek et al. 2018; 
Sung et al. 2018). Collectively, these data suggest that QSOX1 is a viable biomarker and 
target for treatment. 
 Ebselen has been identified as a small molecule inhibitor of QSOX1 (Hanavan et 
al. 2015). Treatment of pancreatic and renal cancer cell lines with ebselen caused 
significant decreases in cell invasion, similarly to the effect of knocking down QSOX1 
expression with shRNAs. Additionally, when nude mice with human tumors were treated 
with ebselen, tumor growth was suppressed over a 28-day period. The interaction 
between ebselen and QSOX1 was determined by liquid chromatography mass 
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spectrometry (LC-MS) to be covalent binding to sulfhydryl groups. Further, it was shown 
by CDAP (1-Cyano-4-dimethylaminopyridinium tetrafluoroborate) treatment and matrix 
assisted laser desorption/ionization mass spectrometry (MALDI-MS) that the free 
cysteines available for ebselen to bind to are C165 and C237. These results suggest that 
drugs targeting QSOX1 may serve as viable treatment options for slowing the 
progression of tumors in patients. 
 With mounting evidence supporting the notion that the enzymatic activity of 
QSOX1 facilitates cell invasion and tumor growth, the hypothesis that inhibiting QSOX1 
would have clinically relevant anti-neoplastic effects continues to grow stronger. In 
continuation with this idea, it was hypothesized that monoclonal antibodies against 
QSOX1 could inhibit tumor cell invasion in vitro. Additionally, development and 
characterization of these antibodies could serve as an important tool in future studies of 
QSOX1; for example, in determining localization, quantifying concentration in fluid 
samples, etc. 
 In this work, QSOX1 was cloned and expressed recombinantly in a eukaryotic 
expression system along with three mutants of QSOX1. Hybridomas were made against 
rQSOX1 and screened for binding and inhibition of QSOX1 activity. Two monoclonal 
antibodies were selected, 2F1.14 and 3A10.6. The variable region genes of these two 
antibodies were cloned and sequenced. The epitope of 2F1.14 was mapped by evaluating 
binding of the mAbs to rQSOX1 mutants. Lastly, both mAbs were characterized on a 
cell-free fluorescent QSOX1 activity assay and a 3D invasion assay with patient-derived 
renal cancer cells. 
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METHODS 
 
Cell culture  
RCJ-41T2 cells were cultured at 37°C with 5% CO2 in a humidified incubator. 
HEK293F cells were incubated at 37°C with 8% CO2 on an orbital shaker set at 135 rpm 
in a baffled flask. RCJ-41T2 (renal carcinoma) cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Corning) supplemented with 10% fetal bovine serum 
(FBS) (Atlanta Biologicals), 100 µg/mL penicillin/streptomycin (Gibco), and 2 mM 
GlutaMAX (Gibco). Hybridoma cells were cultured in DMEM supplemented with 5% 
FBS, 100 µg/mL penicillin/streptomycin, and 2 mM GlutaMAX.  HEK293F cells were 
cultured in Freestyle 293 Expression Medium (Gibco).  
 
rQSOX1 expression and purification  
The short form of the QSOX1 gene was amplified from MCF7 cDNA, obtained 
with a Cells-to-cDNA kit (Ambion), using Phusion Flash Master Mix (Thermo) and 
cloned into pcDNA3.1 V5/His A (Thermo) using Cold Fusion cloning (System 
Biosciences). Positive transformants were verified via colony PCR. Verified 
transformants were cultured in 5 mL LB Amp for 16 hour at 37°C shaking at 225 rpm. 
Plasmids were extracted from 5 mL cultures in LB-Amp using the GeneJET Plasmid 
Miniprep Kit (Thermo). Sequences were confirmed by Sanger sequencing (Arizona State 
University Biodesign Institute Genomics Core). Plasmid was mass-produced in 300 mL 
cultures and extracted using the Nucleobond Xtra Maxi Plus kit (Macherey-Nagel). 
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Figure 2: Purification of rQSOX1 produced by 293F cells. A) Elution profile of 
rQSOX1. MW = 180 kDa PageRuler Prestained Protein Ladder (Thermo), SM = starting 
material, FT = Ni2+/IDA column flow through, BW = binding buffer wash, E1-8 = elution 
fractions. B) LC-MS data in Scaffold showing rQSOX1 expressed in 293F cells had over 
95% probability of being the short form (isoform 2) of QSOX1 with 208 spectral hits and 
52% coverage of QSOX1. C) Fluorescence-based QSOX1 activity assay of purified 
rQSOX1 with a positive control (35 µM H2O2, no rQSOX1) and a negative control (no 
rQSOX1). λex=320 nm, λem=420 nm. 
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 293F cells were seeded at 0.7*106 cells/mL 24 hours before transfection for a cell 
density of 1*106 cells/mL on the day of transfection. An equal ratio of plasmid (µg), 
Freestyle MAX Reagent (Invitrogen) (µL), and total cell volume (mL) was used (i.e. 30 
µg plasmid, 30 µL Freestyle MAX Reagent, 30 mL cell volume). Plasmid and 
transfection reagent were diluted in OptiPro SFM (Gibco) to a total volume of 0.6 mL 
each. Plasmid and transfection reagent were combined and incubated together at room 
temperature for 10 min. The DNA-lipid mixture was added to the 293F cells dropwise 
while swirling the flask. Transfected cells were incubated at 37°C, 8% CO2 shaking at 
135 rpm for 6-7 days, at which point the media was harvested. 
 rQSOX1 protein was purified on a Ni2+/IDA His-bind Resin column (EMD 
Millipore) charged with 100 mM nickel sulfate. The column was washed with 50 mM 
imidazole to remove any nonspecific proteins that bound. Protein was eluted in fractions 
of 100 mM imidazole. The column was recharged by removing Ni2+ from the column 
with stripping buffer (20 mM Tris, 100 mM EDTA, 500 mM NaCl), washing with PBS, 
and storing in 100 mM nickel sulfate. Imidazole elution fractions were run on an SDS-
PAGE gel to check for purity (Figure 2). Pure fractions were dialyzed into PBS and 
concentrated using a 30 kDa Amicon Pro centrifugal filter (EMD Millipore). rQSOX1 
was stored at -80°C. 
 rQSOX1 was run on Orbitrap liquid chromatography mass spectrometry (LC-MS) 
(Thermo) to confirm the identity of the protein, as previously described (Mitchell et al. 
2018). In brief, rQSOX1 was reduced with 10 mM dithiothreitol (DTT) (G Biosciences) 
for 30 min at 60°C, alkylated with 55 mM iodacetamide (IAA) for 30 min at room 
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temperature protected from light, and digested with 20 ng/µL trypsin (Thermo) for 16 
hours at 37°C at pH=8. 5% formic acid was added to stop trypsin digestion. Samples 
were lyophilized and rehydrated in 0.01% formic acid, then loaded into autosampler 
vials. 
 
rQSOX1 mutagenesis 
 QSOX1 in pcDNA3.1 V5/His A was used as a template for mutagenesis. Primers 
were designed to introduce missense mutations at t217a, t1345a, and t1354a to change 
the cysteines in the active site to serines (C73S, C449S, C452S). The point mutation was 
introduced in the middle of a 24-nucleotide long primer. These primers were used with 
the normal forward and reverse primers to amplify fragments in the 5’ and 3’ directions 
from the mutation site. These fragments were spliced by overlap extension (SOE) to 
generate the complete mutant QSOX1 gene. Mutant genes were cloned, expressed, 
purified, and stored as before with the short form of QSOX1. 
 
Generation of monoclonal antibodies 
 Three Balb/c mice were immunized with 100 µg rQSOX1 in Magic Mouse 
Adjuvant (Creative Diagnostics) and boosted twice with rQSOX1 two weeks after 
primary immunization and two weeks after the first boost. The spleen was excised and 
processed using a 0.44 µM mesh filter (Corning). Splenocytes were fused with P3x63 
myeloma fusion partner cells (Kearney et al. 1979) using polyethylene glycol (PEG). 
Hybridomas were cultured in HAT media for two weeks to kill unfused P3x63 myeloma 
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cells, while providing nutrients for hybridomas. Unfused B cells died due to their short 
lifespan in culture. Single-cell cultures of hybridomas were obtained by limiting dilution 
(1 cell per three wells) and evaluated by enzyme-linked immunosorbent assay (ELISA) 
against rQSOX1 and chitin synthase 1 (rCTS1) as a control for non-specificity. Clones 
that produced a high signal by ELISA were subcloned and evaluated by western blot 
against rQSOX1 and rQSOX1 mutants, and by cell-free fluorescence assay to measure 
inhibition of QSOX1 activity. The clones 3A10.6 and 2F1.14 were selected for use in 
further experiments. 
 
ELISA 
 ELISA was used to screen the hybridoma subclones for binding to rQSOX1. 
rQSOX1 was coated onto a high-binding, 96-well Costar Assay Plate (Corning) at 1 
µg/mL in 100 µL for 1 hour at 37°C. Wells were washed with 200 µL PBST (0.05% 
Tween-20) twice and blocked with 1% BSA in PBST (Thermo) for 1 hour at room 
temperature or overnight at 4°C. Wells were probed with 100 µL of hybridoma 
supernatant for 1 hour at room temperature. Binding of primary antibodies was detected 
with 100 µL goat anti-mouse (GαM) IgG secondary antibody conjugated with 
horseradish peroxidase (HRP) (Jackson Immunoresearch Laboratories) diluted at 1:5000 
in blocking buffer for 1 hour at room temperature. Wells were developed with 100 µL 
TMB substrate (BD Biosciences) for 10-15 min. Development was stopped with 100 µL 
0.16 M sulfuric acid. Plates were read on a VersaMax tunable plate reader (Molecular 
Devices). 
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Western Blot 
 Western blot screening of αQSOX1 hybridomas involved running 1 μg of 
rQSOX1 on a SDS-PAGE gel and transferring the proteins to a PVDF membrane. The 
membrane was blocked with 1% BSA in TBST (Thermo) and cut into strips. Each strip 
was probed with 1 mL of supernatant from a different hybridoma clone for 1 hour at 
room temperature. Binding of antibodies from hybridoma supernatants was detected with 
goat anti-mouse IgG antibody conjugated to alkaline phosphatase (Jackson 
Immunoresearch Laboratories) diluted 1:5000 in blocking buffer for 1 hour at room 
temperature. Blots were developed with 1-Step NBT/BCIP (Thermo) for 10-15 min. 
Development was stopped by washing out developing solution with dH2O. 
 
Purification of monoclonal antibodies 
 Media from hybridoma cultures were collected every 5-7 days by centrifuging 
cells and harvesting the supernatant from the pellet. Supernatant was diluted 1:1 in PBS 
to neutralize the pH for purification on Protein A/G. Diluted supernatant was run through 
a column made with 1 mL of Protein A/G Agarose slurry (Pierce). The column was 
washed twice with PBS, then eluted with 100 mM glycine, pH=3.0. Elution fractions 
were neutralized with 100 µL 1M Tris, pH=9.0 per 1 mL elution buffer. Supernatant, 
flow through, and elution fractions were run on an SDS-PAGE gel to analyze purity 
(Figure 3). Elution fractions with pure antibody were pooled and dialyzed into PBS using 
a 10 kDa Amicon Pro centrifugal filter. Antibodies were stored at -20°C. 
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Figure 3: Purification of αQSOX1 mAbs produced by hybridoma clones 2F1.14 and 
3A10.6. Elution profile of αQSOX1 mAbs. MW = 180 kDa PageRuler Prestained Protein 
Ladder (Thermo), SM = starting material, FT = Protein A/G Plus purification flow 
through, E1-5 = 100 mM glycine elution fractions. Heavy chain (IgH) and light chain 
(IgL) are labelled at ~50 kDa and ~25 kDa, respectively. 
 
Gene rescue of QSOX1 mAb variable regions  
 The heavy and light chain variable region genes of 2F1.14 and 3A10.6 were 
amplified from their respective hybridoma cell cDNA, obtained with a Cells-to-cDNA 
kit, using published universal degenerate primers for amplification of murine IgG 
variable heavy and light chain genes (Wang et al. 2000). These primers were altered to 
add homologous ends to the amplicons which are required for Cold Fusion cloning into 
pcDNA3.1 V5/His A. The variable regions were cloned and sequenced as before with the 
short form of QSOX1. The sequences were analyzed in IgBLAST to annotate the 
framework (FRs) and complementarity determining regions (CDRs). The variable light 
chain sequences were checked against the sequence of the NS-1 (P3/NS1/1-Ag4-1) 
myeloma variable light chain sequence (Ning et al. 2012) to verify the determined 
sequence corresponded to the αQSOX1 mAb. Sequences were aligned with the Fass 
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group’s αQSOX1 single-chain variable fragment mAb 492.1 (Grossman et al. 2013) 
using EMBOSS Water (EMBL-EBI) on default settings. 
 
Epitope Mapping  
 MAbs 2F1.14 and 3A10.6 were investigated for binding characteristics to wild 
type (WT) and mutant QSOX1. 1 µg of WT, C73S, C449S, and C452S QSOX1 was 
loaded on a SDS-PAGE gel. The proteins were transferred onto a PVDF membrane and 
blocked with 1% BSA in TBST (Thermo). The blots were probed with 3A10.6 and 
2F1.14 at 1 µg/mL in blocking buffer for 1 hour at room temperature with a control 
lacking primary antibody. Binding of primary antibodies was detected and developed as 
discussed before, with the exception of the time of development being 5 min. 
 
QSOX1 enzymatic activity assay  
 The enzymatic activity of rQSOX1 was measured in an assay that utilizes the 
H2O2 byproduct of QSOX1 in a secondary reaction involving the dimerization of 
homovanillic acid (HVA) by HRP, which produces a fluorescent signal (Raje, Glynn, and 
Thorpe 2002). This assay was performed in a black opaque 96-well flat-bottom plate 
(Corning), in which 150 µM DTT (300 µM thiols) was added to 100 nM rQSOX1, 1 mM 
HVA, 1.4 µM HRP, and 300 µM EDTA in PBS. A positive control consisted of replacing 
rQSOX1 with 35 µM H2O2 to ensure the secondary reaction was functional. H2O2 was 
added with DTT, as HRP immediately acts on H2O2 upon its addition. A negative control 
consisted of all reagents in the assay except rQSOX1. Antibodies were added ~10 
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minutes before the addition of DTT. The vehicle control was 50% glycerol in PBS. 
Controls for antibody interaction with the secondary reaction involved adding antibody to 
the positive control reaction. The final reaction volume was 150 µL. Relative 
fluorescence was measured in a SpectraMax M Series Microplate Reader (Molecular 
Devices) at λex=320 nm and λem=420 nm every 20 sec for 10 min at room temperature. 
 
3D invasion assay  
 A 3D model for invasion experiments reflects a more biologically relevant 
environment of a tumor growing in tissue (Vinci, Box, and Eccles 2015). RCJ-41T2 cells 
were seeded in a Costar 96-well Ultra-Low Adhesion U-bottom plate (Corning) at 1,250 
cells/mL, or the number of cells that formed a spheroid between 300-500 µm, in 200 µL. 
Cells were incubated for 4 days at 37°C, 5% CO2 to form spheroids. Being careful not to 
disturb the spheroids, 150 µL of media was removed from each well. Antibodies and 
vehicle treatments were added at a 6X concentration in 50 µL such that the final 
concentration was appropriate. 100 µL of Matrigel (Corning) was added to each well and 
incubated for 1 hour at 37°C to allow the matrix to solidify. 100 µL of media was added 
on top of the solid matrix. The spheroids were incubated in matrix for 7 days, taking 
bright field images each day. Images were analyzed in ImageJ using grayscale threshold 
analysis to calculate the size of each spheroid and invading cells.  
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RESULTS 
 
Loss of enzymatic activity of rQSOX1 mutants 
 Sanger sequencing results showed that only the intended missense mutations 
(C73S. C449S, C452S) occurred during mutagenesis of rQSOX1. rQSOX1 active site 
mutants were added at equal concentration to WT rQSOX1. Reactions were all run for 10 
min after addition of DTT substrate. All three mutants showed a loss of enzymatic 
activity compared to the WT rQSOX1 as indicated by the significantly reduced relative 
fluorescence in the mutant wells (Figure 3). These results corroborate the results of other 
groups which also showed that the mutation of cysteines in the CxxC motifs in the active 
site of QSOX1 causes a loss of function. 
 
 
Figure 4: Loss of enzymatic activity by rQSOX1 active site mutants compared to 
wild-type (WT) rQSOX1. rQSOX1 mutants were added to the QSOX1 enzymatic 
activity assay at an equal concentration to WT rQSOX1. Relative fluorescence (RFU) 
was measured 10 min after the addition of DTT. λex=320 nm, λem=420 nm. Error bars 
are standard deviation. Statistical significance determined by t-test; **** p<0.0001. 
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QSOX1 monoclonal antibody screening 
 Clones that were positive by indirect ELISA were tested by western blotting. 
rQSOX1 was probed with supernatant from each hybridoma clone (Figure 4A). 3A10 
appeared to be the clone that produced the strongest band while maintaining a low 
background relative to other high binding antibodies. 2F1 appeared to bind weakly to 
rQSOX1; however, it bound better than other inhibitory antibodies, which appeared to 
also bind weakly. Clones that showed moderate to strong binding by western blot were 
tested in a cell-free fluorescence assay to measure the inhibition of the enzymatic activity 
of QSOX1. Supernatant from each clone was added to QSOX1 ~10 min before the 
addition of DTT. 2F1, 1B9, and 1C5 appeared to inhibit QSOX1 (Figure 4B). Because of 
their characteristics shown in the screening results, 2F1 and 3A10 were chosen subcloned 
to select for the high-producing clones, resulting in 2F1.14 and 3A10.6 
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Figure 5: Screening of αQSOX1 hybridomas. A) Western blots showing binding of 
mAbs in hybridoma supernatant to rQSOX1. Binding of mAbs was detected by GαM 
IgG-AP and developed with NBT/BCIP. 2F1 and 3A10 are marked in red. B) QSOX1 
enzymatic activity assay showing inhibition of rQSOX1 by four mAb clones. Hybridoma 
supernatants were incubated with rQSOX1 for ~10 min before addition of DTT. Relative 
fluorescence (RFU) was measured 10 min after the addition of DTT. λex=320 nm, 
λem=420 nm. Error bars are standard deviation. 2F1 and 3A10 are marked in red. 
 
Variable region sequence alignment  
 The variable heavy and variable light chain genes for both αQSOX1 mAbs were 
aligned with the Fass group’s scFv 492.1 mAb in EMBOSS Water. The 2F1.14 variable 
heavy gene was 87.3% similar with a gap in CDR3. CDR1 and CDR2 were almost 
identical with only one amino acid difference in both, with minor similarity (Figure 6A). 
CDR3, however, was different with only 4 complementary amino acids and a gap in the 
2F1.14 sequence. The 2F1.14 variable light gene was almost identical with 94.4% 
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identity and 98.1% similarity (Figure 6B). Between the three variable light CDRs, all but 
one residue were identical, and that one residue had minor similarity. 
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Figure 6: EMBOSS Water alignment of αQSOX1 mAb and Fass group αQSOX1 
scFv mAb 492.1 variable region genes. A) 2F1.14 VH, B) 2F1.14 VL, C) 3A10.6 VH, 
D) 3A10.6 VL. Alignments were run on default settings. Complementarity determining 
regions (CDRs) are underlined. Identity, similarity, gaps, and score are shown. 
 
The 3A10.6 variable heavy and light chain genes had lesser similarity with 67.8% 
similarity between the heavy chains and 79.6% similarity between the light chains 
(Figure 6C and 6D). Additionally, both heavy and light variable regions had six gaps in 
the CDRs. 
 
Inhibition of rQSOX1 enzymatic activity 
2F1.14 and 3A10.6 mAbs were added at 15 µg/mL, 7.5 µg/mL, and 3.75 µg/mL 
with a vehicle of an equal volume of 50% glycerol in PBS. Additionally, each antibody 
was added at 15 µg/mL with a vehicle to control wells testing antibody inhibition of the 
HRP reaction by replacing rQSOX1 with exogenous H2O2. This control was included to 
ensure that any change in fluorescence was the result of the antibodies interacting with 
rQSOX1 and not with HRP. 
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Figure 7: Inhibition of rQSOX1 enzymatic activity by A) 2F1.14 and lack thereof by 
B) 3A10.6. Anti-QSOX1 mAbs were incubated with rQSOX1 in the presence of HVA 
and HRP for 10 minutes. DTT substrate was added and the reaction proceeded for 15 
minutes at which relative fluorescence was measured. Vehicle is 50% Glycerol in PBS 
instead of mAb (1.67% Glycerol total). Relative fluorescence units (RFU) are shown on 
the Y-axis and mAb concentration is shown on the X-axis. Incubation of mAbs with HRP 
and H2O2 in the absence of rQSOX1 to control for potential non-specificity of mAbs 
binding to and inhibiting HRP is shown for C) 2F1.14 and D) 3A10.6. Relative 
fluorescence (RFU) was measured 10 min after the addition of DTT. λex=320 nm, 
λem=420 nm. Error bars are standard deviation. Statistical significance determined by t-
test; *** p<0.001, ** p<0.01. 
 
The addition of 2F1.14 to the assay caused a significant reduction in fluorescence 
with increasing concentrations of antibody from ~2200 RFU to <~800 RFU (Figure 7A). 
In the control wells, 2F1.14 did not cause any significant change in fluorescence with 
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consistent levels at ~1800 RFU (Figure 7C). On the other hand, addition of 3A10.6 did 
not cause any significant change in the wells either with rQSOX1 or the control wells 
without rQSOX1 (Figure 7B and 7D). 
This data suggests that 2F1.14 inhibited the activity of rQSOX1. It was possible 
that 2F1.14 bound to rQSOX1 at or around the active site, blocking the access of 
substrates for QSOX1. It appeared that 3A10.6 did not inhibit QSOX1, despite showing 
high signal by ELISA, suggesting that 3A10.6 did not bind in a region critical to the 
enzymatic function of QSOX1. An important note is that DTT is not a biologically 
relevant substrate because it is a chemical, not a protein. A more informative experiment 
would use the reduced form of a known substrate of QSOX1, if they were known. It is 
likely that laminin α4 and fibronectin are substrates based on data suggesting that 
QSOX1 plays a role in depositing laminin α4 and fibronectin into the extracellular 
membrane and could be used in this assay for more biologically relevant results. 
 
Epitope mapping 
 Mutants of QSOX1 were constructed in which cysteines in the enzymatically 
active CxxC motifs were mutated to serines (C73S, C449S, and C452S). These mutants 
were used in western blot analysis of 2F1.14 and 3A10.6 (Figure 8). The western blot 
shows that while 2F1.14 binds to WT rQSOX1, it does not bind to the C73S mutant of 
QSOX1. This data suggests that C73 is included in or influences the epitope of 2F1.14. 
This result corroborates the findings in the QSOX1 enzymatic assay which showed that 
2F1.14 inhibited QSOX1 activity likely because C73 in the Trx-like domain is involved 
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in initial shuffling of sulfhydryls as client proteins are oxidized by QSOX1. Binding of 
2F1.14 to the active site of QSOX1 would prevent substrates from accessing the active 
site, preventing catalysis and oxidation of the substrates. 
 
 
Figure 8: Epitope mapping of 2F1.14 mAb. Wild-type (WT) and mutated QSOX1 were 
probed with anti-QSOX1 mAbs by western blot. When probed with 2F1.14, bands 
corresponding to QSOX1 (~72 kDa) appear for all QSOX1 variants except for the C73S 
QSOX1 mutant. With 3A10.6, bands appear at 72 kDa for each QSOX1 variant. 
 
Inhibition of invasive phenotype in 3D invasion assay 
  RCJ-41T2 spheroids were treated with 50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 
μg/mL, 3.125 μg/mL, and 1.5625 μg/mL of anti-QSOX1 mAb, and Matrigel was 
prepared according to manufacturer instructions. At 50 μg/mL and 25 µg/mL, both 
3A10.6 and 2F1.14 showed significant inhibition of invasion (Figure 9). The observed 
inhibitory activity of 3A10.6 is curious considering the cell-free enzymatic assay showed 
that 3A10.6 does not inhibit rQSOX1. One possible explanation for this phenomenon is 
that 3A10.6 sterically inhibits the biological substrates of QSOX1 from interacting with 
the active site without binding directly to the active site. As mentioned earlier, the 
substrate used in the fluorescence assay was DTT, which is a very small molecule and 
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may be small enough to still interact with QSOX1 at the active site with 3A10.6 bound, 
while biological substrates may be significantly larger and be blocked by 3A10.6 from 
interacting with QSOX1. 
 
 
Figure 9: Inhibition of invasion in 3D spheroid invasion assay with RCJ-41T2 cells 
treated with A) 2F1.14 and B) 3A10.6. Anti-QSOX1 mAbs were incubated with tumor 
spheroids for 1 h. Matrigel was added and spheroids were incubated for 7 days. Vehicle 
is PBS instead of mAb. Statistical significance determined by t-test; ** p<0.01, * p<0.05. 
 
 One explanation for the high concentration of mAbs required for suppression of 
spheroid invasion may be the presence of QSOX1 in Matrigel because Matrigel is made 
up of the extracellular matrix proteins from mouse sarcoma cells and QSOX1 is secreted 
into the extracellular matrix. QSOX1 in Matrigel could inhibit the antibody from binding 
to the spheroid-derived QSOX1, which would presumably reduce the inhibition of cell 
invasion by the antibodies. However, we have not tested Matrigel for the presence of 
QSOX1. 
Additionally, a rescue experiment is planned to determine if addition of 
exogenous rQSOX1 will rescue the invasive phenotype of spheroids. This assay would 
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also include a non-specific mAb to control for the addition of a mAb to the spheroids. 
When this experiment was conducted, it was presumed that 3A10.6 was the control mAb 
based on the results of the enzymatic activity assay and the epitope mapping; however, 
the results of the 3D invasion assay indicate that this presumption is incorrect. 
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DISCUSSION 
 
 Through hybridoma technology, hundreds of clones of αQSOX1 mAbs were 
generated. After subsequent rounds of screening by ELISA and subcloning by limiting 
dilution, two mAbs were selected, 2F1.14 and 3A10.6. Compared to 3A10.6, 2F1.14 
reacted much less strongly to rQSOX1 based on optical density in ELISA and reactivity 
to rQSOX1 in western blotting. One might presume the weaker binding is due to lower 
affinity, but 2F1.14 binds to an epitope containing the active site of the enzyme. It is 
possible that consistent hinge-like movement of QSOX1 disallows the antibody from 
binding strongly, or that the state of QSOX1 in which the two distant CxxC motifs are 
close disallows binding of 2F1.14. Future studies may involve measuring the affinities of 
both 3A10.6 and 2F1.14 for QSOX1. 
The epitope of 2F1.14 was mapped to include or be influenced by C73, as 
suggested by the absence of a band corresponding to the C73S rQSOX1 mutant by 
western blot (Figure 6). The alignment of these antibodies with the only other published 
αQSOX1 mAb sequence suggests that each of these antibodies are novel antibodies. It is 
interesting to note that scFv 492.1 was also reported to bind to the active site of QSOX1, 
which is a possible explanation for why the variable region on the light chain of each 
antibody are so similar (98.1%); however, there is evidence that suggests that it is the 
heavy chain of the antibody that determines the epitope of the antibody (Wu and Kabat 
1970). 
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 Based on the results of the activity assay, it was thought that only 2F1.14 bound 
and inhibited the activity of QSOX1 while 3A10.6 bound but did not inhibit the activity 
of QSOX1 because the addition of 2F1.14 caused the fluorescent signal to decrease while 
the addition of 3A10.6 did not cause any significant change in fluorescent signal. This 
thought was rejected, however, by the results of the 3D invasion assay which showed that 
both 2F1.14 and 3A10.6 caused a suppression of invasion by the RCJ-41T2 spheroids, 
which is likely to be the result of inhibition of QSOX1. As mentioned previously, the 
substrate used in the enzymatic activity assay was DTT, which is a small, 154 Da 
molecule. This is important to note because the client substrates of QSOX1 in the ECM 
that QSOX1 acts on in the 3D invasion assay are unlikely to be as small as DTT. Thus, it 
is possible that 3A10.6 binds to QSOX1 near but not at the active site, and the presence 
of the antibody sterically inhibits large, client substrates from accessing the active site of 
QSOX1. In other words, 3A10.6 does not inhibit the activity of QSOX1; rather, 3A10.6 
may inhibit the substrates from entering the active site of QSOX1. This could be further 
investigated by reducing possible client substrates and testing them in the enzymatic 
activity assay with the addition of 3A10.6. Possible substrates include ECM proteins like 
fibronectin, laminin α4, collagen, decorin, and tenascin. 
Because of this apparent inhibition of the biological function of QSOX1 by 
3A10.6, the 3D invasion assay does not have a proper control for the addition of IgG to 
the spheroids because 3A10.6 was thought to be that control. To determine if the change 
in phenotype caused by the addition of 2F1.14 and 3A10.6 was truly due to their 
interaction with QSOX1, a non-specific mAb would need to be added to the assay. This 
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antibody should not bind to anything in the assay, so a mAb against a completely 
unrelated protein could be used. Additionally, rescue of invasive activity with the 
exogenous addition of rQSOX1 would assist in further determination that the suppression 
of invasion is caused by the mAb interaction with QSOX1. Additionally, a false rescue 
with the enzymatically inactive rQSOX1 mutants would control for the addition of 
QSOX1 causing an increase in invasion, as opposed to the activity of QSOX1 itself. 
The inhibitory activity of 2F1.14 and 3A10.6 outside of the spheroids suggests 
that QSOX1 is secreted by cells and that the activity of QSOX1 that contributes to cell 
invasion is done in the ECM, not in the Golgi apparatus or ER. This is interesting because 
one of the foundational studies of QSOX1 in cancer found a peptide from QSOX1-L in 
PDA patient plasma (Antwi et al. 2009), but QSOX1-L is primarily localized to the Golgi 
apparatus (Stirling et al. 2007). These observations may support the hypothesis that 
QSOX1-L is proteolytically processed upon secretion (Rudolf, Pringle, and Bulleid 
2013), and that the QSOX1 peptide found in PDA patients was linked to the cleaved 
portion of QSOX1-L, not the entire long isoform. The QSOX1 mAbs could be used in 
conjunction with an antibody against the extra residues included in QSOX1-L to look at 
the difference in QSOX1 concentration between QSOX1-S and QSOX1-L in the ECM 
and in conditioned cell culture media. The secretion of QSOX1 found here also supports 
the findings of Ilani et al. (2013) in which QSOX1 knockdown cells showed a disruption 
of the composition of the ECM and a decrease in cell attachment, and the exogenous 
addition of rQSOX1 refolded the ECM and restored cell attachment. In conjunction with 
the idea that the activity of QSOX1 that facilitates invasion occurs outside of the cell, this 
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data could suggest that the composition and folding of the ECM is important in cell 
invasion, and that the reason for increased expression of QSOX1 by cancer cells could be 
to configure the ECM in a way that allows the cells to invade and metastasize. 
The results of these experiments support the hypothesis that mAbs against 
QSOX1 inhibit invasion in vitro. These findings are consistent with other literature which 
concluded that QSOX1 plays a role in facilitating invasion and that inhibition of QSOX1 
by either shRNAs or small molecules reduced the invasive phenotype of tumor cells. 
These mAbs allow for specific inhibition of QSOX1 without needing to transduce or 
transfect cells. Another possible use for these mAbs is detecting QSOX1 in biological 
samples to investigate QSOX1 as a potential biomarker of cancer or cancer progression. 
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